AI assistant
STANDARD BIOTOOLS INC. — Director's Dealing 2011
Feb 10, 2011
32853_dirs_2011-02-10_1bb2f519-016e-4ab2-804d-37a15dc69373.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: FLUIDIGM CORP (FLDM)
CIK: 0001162194
Period of Report: 2011-02-09
Reporting Person: EDB Investments Pte Ltd. (10% Owner)
Reporting Person: Biomedical Sciences Investment Fund Pte Ltd. (10% Owner)
Reporting Person: SINGAPORE BIO INNOVATIONS PTE LTD (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series E Preferred Warrant (Right to Buy) | $24.22 | Common Stock (43853) | Direct | ||
| Series E Preferred Stock | $0 | Common Stock (1047955) | Direct | ||
| Series D Preferred Stock | $0 | Common Stock (623531) | Direct | ||
| Series C Preferred Stock | $0 | Common Stock (128025) | Direct |
Footnotes
F1: Reflects the automatic conversion of each share of Series E Preferred Stock into 1.3 shares of Common Stock to occur upon the closing of the Issuer's initial public offering.
F2: Expires immediately prior to the closing of the Issuer's initial public offering.
F3: Biomedical Sciences Investment Fund Pte ltd is the record holder of the securities reported on Lines 1, 2 and 3 of Table 2.
F4: EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, one of the Issuer's directors, is a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
F5: Reflects a 1-for-1.73 reverse stock split of the Issuer's outstanding shares effected on February 3, 2011.
F6: Each share has no expiration date.
F7: Reflects the automatic conversion of each share of Series C Preferred Stock and Series D Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering. Each share has no expiration date.
F8: Singapore Bio-Innovations Pte Ltd is the record holder of the securities reported on Line 4 of Table 2.